Losartan benefits over atenolol in non‐smoking hypertensive patients with left ventricular hypertrophy: The LIFE study

References

• Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens 1990; 8 Suppl 5: S3–8.
   PubMed Web of Science ®Google Scholar
• Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. Br Med J 1989; 298: 789–94.
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001; 103: 163–82.
   PubMed Web of Science ®Google Scholar
• Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–60.
   Google Scholar
• Winniford MD. Smoking and cardiovascular function. J Hypertens 1990; 8 Suppl 5: S17–23.
   Google Scholar
• Craig WY, Palomäki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Br Med J 1989; 298: 784–8.
   PubMed Web of Science ®Google Scholar
• Khalili P, Nilsson PM, Nilsson JA, et al. Smoking as a modifier of the systolic blood pressure-induced risk of cardiovascular events and mortality: a population-based prospective study of middle-aged men. J Hypertens 2002; 20: 1759–64.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10: 705–13.
   Google Scholar
• Dahlöf B, Devereux RB, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32: 989–97.
   Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a ran-domised trial against atenolol. Lancet 2002; 359: 995–1003.
   Google Scholar
• Okin PM, Devereux RB, Jern S, et al. Baseline characteris-tics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan interven-tion for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension 2000; 36: 766–73.
   PubMed Web of Science ®Google Scholar
• The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379–92.
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97–104.
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561–72.
   PubMed Web of Science ®Google Scholar
• Wikstrand J, Warnold I, Olsson G, et al. G. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988; 259: 1976–82.
   Google Scholar
• Tuomilehto J, Wikstrand J, Olsson G, et al. Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study. Hypertension 1989; 13: 773–80.
   Google Scholar
• Trap-Jensen J, Carlsen JE, Svendsen TL, et al. Cardio-vascular and adrenergic effects of cigarette smoking during immediate non-selective and selective beta adrenoceptor blockade in humans. Eur J Chin Invest 1979; 9: 181–3.
   Google Scholar
• Tango M, Krogsgaard AR, Trap-Jensen J, et al. Haemody-namic effects of cigarette smoking before and during long-term non-selective and selective beta-adrenergic blockade in patients with arterial hypertension. Acta Med Scand Suppl 1985; 693: 111–14.
   Google Scholar
• Cryer PE, Haymond MW, Santiago JV, et al. Norepineph-rine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976; 295: 573–7.
   PubMed Web of Science ®Google Scholar
• Groppelli A, Giorgi DM, Omboni S, et al. Persistent blood pressure increase induced by heavy smoking. J Hypertens 1992; 10: 495–9.
   PubMed Web of Science ®Google Scholar
• Omvik P. How smoking affects blood pressure. Blood Press 1996; 5: 71–7.
   PubMedGoogle Scholar
• Verdecchia P, Schillaci G, Borgioni C, et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertro-phy in essential hypertension. J Hypertens 1995; 13: 1209–15.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Olsen MH, Dahlöf B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ven-tricular hypertrophy: the LIFE study. J Hypertens 2002; 20: 405–12.
   Google Scholar
• Derby CA, Lapane KL, Hume AL, et al. Is cigarette smoking an effect modifier of the relation between anti-hypertensive therapy and blood lipids? Epidemiology 1997; 8: 48–54.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Perry IJ. Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 2001; 24: 1590–5.
   Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–86.
   Google Scholar
• Puranik R, Celermajer DS. Smoking and endothelial func-tion. Prog Cardiovasc Dis 2003; 45: 443–58.
   PubMed Web of Science ®Google Scholar
• Brasier AR, Recinos A 3rd„ Eledrisi MS. Vascular inflam-mation and the renin-angiotensin system. Arterioscler Thromb Vase Biol 2002; 22: 1257–66.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antago-nist losartan. Circulation 2000; 101: 1653–9.
   PubMed Web of Science ®Google Scholar
• Zhang C, Hein TW, Wang W, et al. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003; 92: 322–9.
   PubMed Web of Science ®Google Scholar
• Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770–6.
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Kaufman DW, Helmrich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med. 1985; 313: 1511–4.
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21: 797–804.
   PubMed Web of Science ®Google Scholar